An injectable signal-amplifying device elicits a specific immune response against malignant glioblastoma

Qiu, Qiujun; Chen, Sunhui; He, Huining; Chen, Jixiang; Ding, Xinyi; Wang, Dongdong; Yang, Jiangang; Guo, Pengcheng; Li, Yang; Kim, Jisu; Sheng, Jianyong; Gao, Chao; Yin, Bo; Zheng, Shihao; Wang, Jianxin

doi:10.1016/j.apsb.2023.06.010

Cited by 3 publications

(1 citation statement)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To confirm this hypothesis, the authors established an orthotopic GB tumor model that was resected on day 14 after tumor engraftment, while the remaining cavity was injected with hydrogel. DOX/RAcNPs synergized with GM-CSF to enhance immune responses, and rats treated with DOX/RAcNPs@gel displayed reduced tumor volume compared with controls or TMZ-treated rats, although all animals died within 32 days (a fact attributed to the insufficient immune infiltrates in the tumor site) [ 981 ].…”

Section: Nanotherapiesmentioning

confidence: 99%

Glioblastoma Therapy: Past, Present and Future

Obrador,

Moreno-Murciano,

Oriol-Caballo

et al. 2024

IJMS

View full text Add to dashboard Cite

Glioblastoma (GB) stands out as the most prevalent and lethal form of brain cancer. Although great efforts have been made by clinicians and researchers, no significant improvement in survival has been achieved since the Stupp protocol became the standard of care (SOC) in 2005. Despite multimodality treatments, recurrence is almost universal with survival rates under 2 years after diagnosis. Here, we discuss the recent progress in our understanding of GB pathophysiology, in particular, the importance of glioma stem cells (GSCs), the tumor microenvironment conditions, and epigenetic mechanisms involved in GB growth, aggressiveness and recurrence. The discussion on therapeutic strategies first covers the SOC treatment and targeted therapies that have been shown to interfere with different signaling pathways (pRB/CDK4/RB1/P16ink4, TP53/MDM2/P14arf, PI3k/Akt-PTEN, RAS/RAF/MEK, PARP) involved in GB tumorigenesis, pathophysiology, and treatment resistance acquisition. Below, we analyze several immunotherapeutic approaches (i.e., checkpoint inhibitors, vaccines, CAR-modified NK or T cells, oncolytic virotherapy) that have been used in an attempt to enhance the immune response against GB, and thereby avoid recidivism or increase survival of GB patients. Finally, we present treatment attempts made using nanotherapies (nanometric structures having active anti-GB agents such as antibodies, chemotherapeutic/anti-angiogenic drugs or sensitizers, radionuclides, and molecules that target GB cellular receptors or open the blood–brain barrier) and non-ionizing energies (laser interstitial thermal therapy, high/low intensity focused ultrasounds, photodynamic/sonodynamic therapies and electroporation). The aim of this review is to discuss the advances and limitations of the current therapies and to present novel approaches that are under development or following clinical trials.

show abstract

Section: Nanotherapiesmentioning

confidence: 99%